研究生教育

徐荣臻 男 医学博士

浙江大学医学院 研究员（三级岗） 博士研究生导师

浙江大学医学院附属第二医院血液科副主任

浙江大学血液病研究所副所长

浙江省医学分子生物学重点实验室副主任

美国Johns Hopkins University访问学者

美国City of Hope国家医学中心访问学者

研究方向：主要从事血液肿瘤分子病因和发病机制及新型分子靶向性抗肿瘤药物的研究与开发，近年来在人白血病和淋巴瘤细胞恶性增殖分子机制、新型分子靶向性抗肿瘤药物的研究领域取得了系列国际前沿原创性成果。

研究成果：已在Cancer cell, Blood, Leukemia, Hepatology, Journal of Hepatology, Oncogene等国际学术期刊上发表原创性SCI研究论文50多篇。已获得授权发明专利（PCT）十多项。2011年获得国家科技进步奖二等奖一项（排名第3）。

科研项目：主持和承担国家自然科学基金12项，“十五”科技攻关项目子课题1项。

获得荣誉：2001年获得美国癌症研究协会Young Investigator Scholar 奖。浙江省151人才。浙江省卫生高层次创新人才。

代表性SCI论文(*通讯作者)

1) Yang L, Wu B, Wu Z, Xu Y, Wang P, Li M, Xu R*, Liang Y*. CAMKIIγ is a targetable driver of multiple myeloma through CaMKIIγ/ Stat3 axis. Aging (Albany NY). 2020;12(13):13668-13683.

2) Yu Q, Xu Y, Zhuang H, Wu Z, Zhang L, Li J, Yang L, Wu B, Wang P, Zhang X, Gan X, Liang Y, Zheng S, Yu X, Gu Y, Xu R*. Aberrant activation of RPB1 is critical for cell overgrowth in acute myeloid leukemia. Exp Cell Res. 2019;384(2):111653.

3) Yu Q, Wang P, Yang L, Wu Z, Li S, Xu Y, Wu B, Ma A, Gan X, Xu R*. Novel synthetic tosyl chloride-berbamine regresses lethal MYC-positive leukemia by targeting CaMKIIγ/Myc axis. Biomed Pharmacother. 2019;117:109134.

4) Gu Y, Zhang J, Ma X, Kim BW, Wang H, Li J, Pan Y, Xu Y, Ding L, Yang L, Guo C, Wu X, Wu J, Wu K, Gan X, Li G, Li L, Forman SJ, Chan WC, Xu R*, Huang W*. Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma. Cancer Cell. 2017;32(1):115-128.

5) Ma X, Meng Z, Jin L, Xiao Z, Wang X, Tsark WM, Ding L, Gu Y, Zhang J, Kim B, He M, Gan X, Shively JE, Yu H, Xu R*, Huang W*. CAMK2γ in intestinal epithelial cells modulates colitis-associated colorectal carcinogenesis via enhancing STAT3 activation. Oncogene. 2017;36(28):4060-4071.

6) Meng Z, Ma X, Du J, Wang X, He M, Gu Y, Zhang J, Han W, Fang Z, Gan X, Van Ness C, Fu X, Schones DE, Xu R*, Huang W*. CAMK2γ antagonizes mTORC1 activation during hepatocarcinogenesis. Oncogene. 2017;36(17):2446-2456.

7) Gu Y, Zheng W, Zhang J, Gan X, Ma X, Meng Z, Chen T, Lu X, Wu Z, Huang W*, Xu R*. Aberrant activation of CaMKIIγ accelerates chronic myeloid leukemia blast crisis. Leukemia. 2016;30:1282-9.

8) Zhou H, Xu R*. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015;6:403-12.

9) Chen T, Meng Z, Gan Y, Wang X, Gu Y, Xu X, Tang J, Zhou H, Zhang X, Gan X, Van Ness C, Xu F, Xu G, Huang L, Zhang X, Fang Y, Wu J, Zheng S, Jin J, Huang W*, Xu R*.The viral oncogene Np9 acts as a critical molecular switch for co-activating β-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells. Leukemia. 2013，27(1):1469-78.

10) Gu Y, Chen T, Meng Z, Gan Y, Xu X, Lou G, Li H, Gan X, Zhou H, Tang J, Xu G, Huang L, Zhang X, Fang Y, Wang K, Zheng S, Huang W*, Xu R*. CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine. Blood. 2012，120(24):4829-39.

11) Meng Z, Wang X, Gan Y, Zhang Y, Zhou H, Ness CV, Wu J, Lou G, Yu H, He C, Xu R*, Huang W*. Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice. J Hepatol. 2012, 57(5):1004-12.

12) Wei Zhang, Xuzhao Zhang, C.Tian, Tao Wang, Phuong Thi Nguyen Sarkis, Yongmin Fang, Shu Zheng, and Xiao-Fang Yu, Rongzhen Xu*. Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses HBV expression. Cell Microbiol. 2008,10:112-21.

13) Rongzhen Xu, Xuzhao Zhang, Wei Zhang, Yongmin Fang, Shu Zheng, and Xiao-Fang Yu. Association of human APOBEC3 cytidine deamineases with the generation of hepatitis B x antigen mutants and hepatocellular carcinoma. Hepatology. 2007,46(6):1810-1820. 

14) Xu R*. Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia. Cell Res. 2007,17(4):295-297.

15) Xu R*, Yu Y, Zheng S, Zhao X, Dong Q, He Z, Liang Y, Lu Q, Fang Y, Gan X, Xu X, Zhang S, Dong Q, Zhang X, Feng GS.Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood. , 2005, 106(9):3142-9.